
    
      This study will include up to 10 different dosing cohorts, with each cohort consisting of 2
      groups (ALXN1820 group, placebo group). Participants will be randomly assigned in a 3:1 ratio
      to each of these 2 groups, respectively, within all 10 cohorts, to receive either a single or
      multiple doses of ALXN1820 SC, a single dose of ALXN1820 IV, or a single or multiple doses of
      placebo.

      The study will be conducted in healthy adult participants and will also include a multiple SC
      dose cohort in healthy participants of Japanese descent.
    
  